Highlights:
· Solid performance delivering underlying operating profit growth of 11.7% at constant exchange rate (CER) (3.6% at actual exchange rate (AER)).
· Group revenue increased by 11.4% at CER (5.2% at AER). This was against a soft comparator period in the prior year.
· Good momentum in Europe with sales growing at 5.7% at CER (decline of 0.6% at AER).
· Substantial sales growth of 60.6% at CER (55.6% at AER) in the US.
· A new differentiated generic food producing animal antibiotic aerosol was approved in Europe.
· Osphos®, our novel equine lameness product, was launched in the US and UK.
· A Canadian subsidiary was established during the period and commenced trading in January 2015.
· Underlying diluted EPS at 20.51 pence, a 30.6% growth at CER (21.1% at AER).
· Interim dividend increased to 5.12 pence per share, a 7.8% increase compared to the prior year.
· Net cash position of £3.0 million.
